HIMS vs. TDOC, AUNA, LFMD, AIRS, SHLT, PTWO, TOI, CANOQ, CCM, and ALNY
Should you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Teladoc Health (TDOC), Auna (AUNA), LifeMD (LFMD), AirSculpt Technologies (AIRS), SHL Telemedicine (SHLT), Pono Capital Two (PTWO), Oncology Institute (TOI), Cano Health (CANOQ), Concord Medical Services (CCM), and Alnylam Pharmaceuticals (ALNY).
Teladoc Health (NYSE:TDOC) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, community ranking, media sentiment, risk, analyst recommendations, valuation and institutional ownership.
76.8% of Teladoc Health shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 1.0% of Teladoc Health shares are owned by insiders. Comparatively, 17.7% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Teladoc Health received 640 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 63.35% of users gave Teladoc Health an outperform vote while only 35.37% of users gave Hims & Hers Health an outperform vote.
Hims & Hers Health has a net margin of -0.24% compared to Hims & Hers Health's net margin of -8.90%. Teladoc Health's return on equity of -0.70% beat Hims & Hers Health's return on equity.
In the previous week, Hims & Hers Health had 9 more articles in the media than Teladoc Health. MarketBeat recorded 23 mentions for Hims & Hers Health and 14 mentions for Teladoc Health. Teladoc Health's average media sentiment score of 0.47 beat Hims & Hers Health's score of 0.14 indicating that Hims & Hers Health is being referred to more favorably in the news media.
Teladoc Health has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.
Hims & Hers Health has lower revenue, but higher earnings than Teladoc Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Teladoc Health, indicating that it is currently the more affordable of the two stocks.
Teladoc Health presently has a consensus target price of $18.22, suggesting a potential upside of 82.19%. Hims & Hers Health has a consensus target price of $16.43, suggesting a potential downside of 30.83%. Given Hims & Hers Health's higher possible upside, research analysts plainly believe Teladoc Health is more favorable than Hims & Hers Health.
Summary
Hims & Hers Health beats Teladoc Health on 12 of the 18 factors compared between the two stocks.
Get Hims & Hers Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hims & Hers Health Competitors List
Related Companies and Tools
